AR and pachyonychia congenita: Despite ADT therapy remaining the treatment of choice for PC patients, drug-resistance often emerges causing castration-resistant disease (CRPC), a tumoral phenotype whose regulatory mechanisms could be mediated by aberrant activity of androgen receptor (AR) signaling pathway (10–13).